2012年，轩竹生物科技股份有限公司（以下简称“轩竹生物”）被四环医药全资收购，此后自2018年起便开启了独立运营的新征程。近年来，公司聚焦于消化系统疾病、肿瘤以及非酒精性脂肪性肝炎（NASH）等关键治疗领域，致力于创新药物的开发。目前，公司正筹备在香港联合交易所主板上市。 然而，轩竹生物的资本化之路并非坦途。2022年，公司首次向科创板发起上市冲击，却在2023年3月的上市委审议环节遭遇暂缓，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.